Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD) reported 3Q20 revenue of $67.4 million, a 38% increase from $48.8 million in 3Q19, affirming its full-year revenue guidance of $250 million to $260 million. The revenue growth is mainly driven by strong demand for Galafold, with compliance rates exceeding 90%. The PROPEL study for AT-GAA is on track for data release in 1Q21, while positive CLN6 gene therapy data has been presented. The company maintains a strong cash position of $509.1 million, supporting ongoing operations through to self-sustainability.
- 3Q20 revenue increased by 38% year-over-year to $67.4 million.
- Company is on track to achieve revenue guidance of $250 million - $260 million for 2020.
- Strong patient demand for Galafold, with compliance rates over 90%.
- 97% of planned infusions for PROPEL study completed on schedule.
- Net loss increased to $64.0 million in 3Q20 from $61.8 million in 3Q19.
- Total GAAP operating expenses rose to $111.8 million, up from $100.5 million.
Galafold 3Q20 Revenue of
AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20
Positive CLN6 Batten Disease Gene Therapy Data Presented in October
Fabry Disease Gene Therapy Clinical Candidate Selected
Conference Call and Webcast Today at 8:30 a.m. ET
CRANBURY, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2020. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “During the third quarter, we made tremendous progress advancing our mission for patients and are on track to achieve our 2020 key strategic priorities, including our global Fabry commercial launch, Pompe late-stage development program, and advancing our industry-leading gene therapy pipeline. Through these efforts, we remain strongly positioned to achieve our vision of delivering groundbreaking new medicines and hopefully, one day, cures for people living with rare diseases.”
Corporate Highlights
- Global revenue for Galafold® (migalastat) in the third quarter of 2020 was
$67.4M . Third quarter revenue represented a year-over-year increase of38% from total revenue of$48.8 million in the third quarter of 2019. On a constant currency basis, third quarter 2020 total revenue was$65.7 million , representing operational revenue growth measured at constant currency exchange rates of35% , which was further benefited by a positive currency impact of$1.7 million , or3% . Galafold performance was driven largely by strong patient demand. Global compliance and adherence rates continue to exceed90% . - Global Phase 3 PROPEL clinical study of AT-GAA in late-onset Pompe disease (LOPD) on track for top-line data in 1Q21. To date,
97% + of the 3,100+ planned infusions and assessments for the ongoing PROPEL study have been completed on schedule. The Company plans to initiate a rolling BLA for AT-GAA in the fourth quarter of 2020, completing final submission in the first half of 2021. - To be highlighted on today’s call, new natural history data from the Amicus POM-002 chart review study in people living with LOPD treated long-term with current standard of care, alglucosidase alfa. Data are consistent with the medical literature and further supports PROPEL design assumptions.
- Additional Phase 1/2 CLN6 data presented at the Child Neurology Society Annual Meeting in October. The data shows a meaningful effect in slowing disease progression out to 24 months compared to natural history. Regulatory interactions are ongoing, and the Company expects to provide feedback on the path forward in 2021.
- Initial data from the Phase 1/2 CLN3 study expected in early 2021. Regulatory interactions are ongoing and the Company expects to provide feedback on the path forward in 2021.
- A gene therapy clinical candidate has been selected for IND enabling studies in Fabry Disease. Initial data from the Company’s AAV gene therapy with an engineered GLA transgene demonstrated significantly better GL-3 reduction than one with wild-type GLA. Full set of preclinical data to be presented at a medical conference in early 2021.
- Cash position sufficient to achieve self-sustainability without the need for any future dilutive financings. The Company continues to carefully manage expenses and investments, while executing on the Galafold launch and advancing development programs.
Third Quarter 2020 Financial Results
- Total revenue in the third quarter 2020 was
$67.4 million , a year-over-year increase of38% from total revenue of$48.8 million in the third quarter of 2019. On a constant currency basis, third quarter 2020 total revenue was$65.7 million , representing operational revenue growth measured at constant currency exchange rates of35% . Reported revenue was aided by a positive currency impact of$1.7 million , or3% . - Cash, cash equivalents, and marketable securities totaled
$509.1 million at September 30, 2020, compared to$452.7 million at December 31, 2019. - Total GAAP operating expenses of
$111.8 million for the third quarter 2020 increased as compared to$100.5 million for the third quarter 2019, reflecting continued investments in our pipeline offset by decreased travel and third-party costs. - Total non-GAAP operating expenses of
$92.4 million for the third quarter of 2020 increased as compared to$89.7 million in the third quarter of 2019, reflecting continued investments in our pipeline offset by decreased travel and third-party costs.1 - Net loss was
$64.0 million , or$0.25 per share, compared to a net loss of$61.8 million , or$0.24 per share, for the third quarter 2019. The third quarter 2020 net loss included an impact of$7.3 million relating to extinguishment of debt.
1 Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for all reporting periods appear in the tables to this press release.
2020 Financial Guidance
- For the full-year 2020, the Company anticipates total Galafold revenue of
$250 million to$260 million based on the average exchange rates for 2019. - Non-GAAP operating expense guidance for the full-year 2020 is
$410 million to$420 million , driven by continued investment in the global Galafold launch, AT-GAA clinical studies, and advancing our gene therapy pipeline.2 - Cash, cash equivalents, and marketable securities totaled
$509.1 million at September 30, 2020. Based on current operating models, the Company believes that the current cash position, along with the net proceeds from the 2020 Senior Secured Term Loan, and expected future revenues are sufficient to fund the Company’s operations and ongoing research programs through to self-sustainability.
2 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure.
Anticipated Milestones by Program
Galafold (migalastat) Oral Precision Medicine for Fabry Disease
- On track to meet full-year 2020 revenue guidance range of
$250 million to$260 million - Continued geographic expansion
- Registry and other Phase 4 studies underway
AT-GAA for Pompe Disease
- Plans to initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020, with addition of complete clinical results for PROPEL in 1H2021 to support full approval
- Additional supportive studies, including an open-label study in 12- to <18-year-olds living with Pompe
Gene Therapy Portfolio
- Advance regulatory discussions to finalize clinical and regulatory path for the CLN6 Batten disease gene therapy development program
- Initial data from the CLN3 Batten disease Phase 1/2 study expected in early 2021 and advance regulatory discussions to finalize clinical and regulatory path
- Continue IND-enabling toxicology work in Pompe disease and progress towards IND
- Additional preclinical data expected across multiple programs
- Manufacturing advancements across portfolio
Conference Call and Webcast
Amicus Therapeutics will host a conference call and audio webcast today, November 5, 2020 at 8:30 a.m. ET to discuss the third quarter 2020 financial results and corporate updates. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7788189.
A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. A replay of the call will be available for seven days beginning at 11:30 a.m. ET on November 5, 2020. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 7788189.
About Galafold
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in over 40 countries around the world, including the U.S., EU, U.K., Japan and others.
U.S. INDICATIONS AND USAGE
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
The most common adverse reactions reported with Galafold (≥
USE IN SPECIFIC POPULATIONS
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.
It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.
Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been established in pediatric patients.
To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.
EU Important Safety Information
Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.
- Galafold is not intended for concomitant use with enzyme replacement therapy.
- Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children 0–15 years of age have not yet been established.
- No dosage adjustments are required in patients with hepatic impairment or in the elderly population.
- There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
- While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk.
- Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.
- It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold.
- OVERDOSE: General medical care is recommended in the case of Galafold overdose.
- The most common adverse reaction reported was headache, which was experienced by approximately
10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS. - Call your doctor for medical advice about side effects.
For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
Non-GAAP Financial Measures
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. Full reconciliations of GAAP results to the comparable non-GAAP measures for the reported periods appear in the financial tables section of this press release. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product. In addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, Japan, the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Statements regarding corporate financial guidance and financial goals and the attainment of such goals. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019, the Quarterly Report filed on Form 10-Q for the quarter ended June 30, 2020, and the Quarterly Report filed on Form 10-Q to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
TABLE 1
Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||
| Net product sales | $ | 67,437 | $ | 48,768 | $ | 190,315 | $ | 126,944 | |||||||||||
| Cost of goods sold | 8,399 | 5,596 | 21,627 | 15,018 | |||||||||||||||
| Gross profit | 59,038 | 43,172 | 168,688 | 111,926 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Research and development | 70,419 | 58,892 | 229,150 | 194,466 | |||||||||||||||
| Selling, general, and administrative | 37,850 | 39,680 | 112,722 | 126,561 | |||||||||||||||
| Changes in fair value of contingent consideration payable | 1,034 | 789 | 2,680 | 2,652 | |||||||||||||||
| Depreciation and amortization | 2,496 | 1,116 | 6,299 | 3,261 | |||||||||||||||
| Total operating expenses | 111,799 | 100,477 | 350,851 | 326,940 | |||||||||||||||
| Loss from operations | (52,761 | ) | (57,305 | ) | (182,163 | ) | (215,014 | ) | |||||||||||
| Other income (expense): | |||||||||||||||||||
| Interest income | 518 | 2,752 | 2,898 | 7,990 | |||||||||||||||
| Interest expense | (6,784 | ) | (4,026 | ) | (14,148 | ) | (15,105 | ) | |||||||||||
| Loss on exchange of convertible notes | — | — | — | (40,624 | ) | ||||||||||||||
| Loss on extinguishment of debt | (7,276 | ) | — | (7,276 | ) | — | |||||||||||||
| Other income (expense) | 3,019 | (3,481 | ) | 29 | (3,272 | ) | |||||||||||||
| Loss before income tax | (63,284 | ) | (62,060 | ) | (200,660 | ) | (266,025 | ) | |||||||||||
| Income tax (expense) benefit | (727 | ) | 251 | (4,791 | ) | (634 | ) | ||||||||||||
| Net loss attributable to common stockholders | $ | (64,011 | ) | $ | (61,809 | ) | $ | (205,451 | ) | $ | (266,659 | ) | |||||||
| Net loss attributable to common stockholders per common share — basic and diluted | $ | (0.25 | ) | $ | (0.24 | ) | $ | (0.80 | ) | $ | (1.13 | ) | |||||||
| Weighted-average common shares outstanding — basic and diluted | 259,161,799 | 254,674,422 | 258,091,170 | 235,527,540 | |||||||||||||||
TABLE 2
Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
| September 30, 2020 | December 31, 2019 | ||||||||
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 210,631 | $ | 142,837 | |||||
| Investments in marketable securities | 298,451 | 309,903 | |||||||
| Accounts receivable | 44,828 | 33,284 | |||||||
| Inventories | 15,767 | 14,041 | |||||||
| Prepaid expenses and other current assets | 15,600 | 20,008 | |||||||
| Total current assets | 585,277 | 520,073 | |||||||
| Operating lease right-of-use assets, less accumulated amortization of | 23,397 | 33,315 | |||||||
| Property and equipment, less accumulated depreciation of | 44,618 | 47,705 | |||||||
| In-process research & development | 23,000 | 23,000 | |||||||
| Goodwill | 197,797 | 197,797 | |||||||
| Other non-current assets | 26,453 | 28,317 | |||||||
| Total Assets | $ | 900,542 | $ | 850,207 | |||||
| Liabilities and Stockholders’ Equity | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 14,764 | $ | 21,722 | |||||
| Accrued expenses and other current liabilities | 89,595 | 99,901 | |||||||
| Operating lease liabilities | 7,368 | 7,189 | |||||||
| Total current liabilities | 111,727 | 128,812 | |||||||
| Deferred reimbursements | 8,906 | 8,906 | |||||||
| Long-term debt | 388,584 | 149,505 | |||||||
| Contingent consideration payable | 16,561 | 22,681 | |||||||
| Deferred income taxes | 5,051 | 5,051 | |||||||
| Operating lease liabilities | 44,627 | 53,531 | |||||||
| Other non-current liabilities | 4,817 | 5,296 | |||||||
| Total liabilities | 580,273 | 373,782 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders’ equity: | |||||||||
| Common stock, | 2,626 | 2,598 | |||||||
| Additional paid-in capital | 2,274,797 | 2,227,225 | |||||||
| Accumulated other comprehensive loss: | |||||||||
| Foreign currency translation adjustment | 4,576 | 2,785 | |||||||
| Unrealized (loss) gain on available-for-sale securities | (56 | ) | 40 | ||||||
| Warrants | 12,387 | 12,387 | |||||||
| Accumulated deficit | (1,974,061 | ) | (1,768,610 | ) | |||||
| Total stockholders’ equity | 320,269 | 476,425 | |||||||
| Total Liabilities and Stockholders’ Equity | $ | 900,542 | $ | 850,207 | |||||
TABLE 3
Amicus Therapeutics, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||
| Total operating expenses - as reported GAAP | $ | 111,799 | $ | 100,477 | $ | 350,851 | $ | 326,940 | |||||
| Research and development: | |||||||||||||
| Share-based compensation | 8,626 | 3,106 | 17,241 | 12,090 | |||||||||
| Selling, general and administrative: | |||||||||||||
| Share-based compensation | 7,282 | 5,737 | 19,671 | 19,432 | |||||||||
| Changes in fair value of contingent consideration payable | 1,034 | 789 | 2,680 | 2,652 | |||||||||
| Depreciation and amortization | 2,496 | 1,116 | 6,299 | 3,261 | |||||||||
| Total operating expense adjustments to reported GAAP | 19,438 | 10,748 | 45,891 | 37,435 | |||||||||
| Total operating expenses - as adjusted | $ | 92,361 | $ | 89,729 | $ | 304,960 | $ | 289,505 | |||||
FAQ
What was Amicus Therapeutics' revenue in 3Q20?
What is the revenue guidance for Amicus Therapeutics in 2020?
When will the PROPEL study results for AT-GAA be released?
What is the cash position of Amicus Therapeutics as of September 30, 2020?
